Erasca (ERAS) Financials

Erasca (NASDAQ: ERAS) remains a cash-rich, pre-revenue biotech, but its operating losses are still substantial and the latest quarter showed a meaningful step-up in spending. Across the last four years, the company has consistently reported no revenue, negative operating income, and recurring net losses, which is typical for a development-stage drug company. The key question for investors is whether Erasca’s large cash and investment balance can fund its pipeline long enough to create clinical and commercial value.

Q1 2026 was especially notable because of the company’s acquisition activity and capital raise. Erasca reported a net loss of $183.4 million, compared with a loss of $29.1 million in Q4 2025 and $30.6 million in Q3 2025. The jump was driven by much higher R&D spending of $177.3 million and a large acquisition-related cash outflow of $150.0 million. At the same time, the company raised $258.8 million through issuance of common equity, which helped offset the heavy investing outflow.

Cash generation from operations remains deeply negative. In Q1 2026, operating cash flow was negative $27.3 million, slightly worse than negative $21.7 million in Q4 2025 and close to prior quarterly levels. Over the last several years, quarterly operating cash burn has generally ranged in the mid-$20 million to low-$30 million area, though recent quarters have been more volatile because of changing non-cash items and investment activity.

Balance sheet liquidity is still strong for now. As of March 31, 2026, Erasca had $47.3 million in cash and equivalents plus $196.5 million in short-term investments and $164.7 million in long-term investments, for total cash and investments of about $408.5 million. Total current assets were $253.8 million and total assets were $461.2 million, while total liabilities were only $67.7 million. That gives the company a solid liquidity cushion, though the acquisition and capital deployment will matter going forward.

Here are the most important takeaways for investors:

• Strong liquidity position: Erasca ended Q1 2026 with more than $408 million in cash and investments, giving it meaningful runway.
• Low debt profile: Total liabilities were only $67.7 million versus $393.5 million in equity, which limits balance sheet risk.
• Equity financing added capital: The company raised $258.8 million from common stock issuance in Q1 2026.
• Interest income helps offset losses: Q1 2026 interest and investment income was $4.4 million, providing some support to pre-tax results.
• No revenue yet: Erasca continues to operate without product revenue, so performance remains entirely tied to pipeline progress.
• Cash flow still supported by investments: The company regularly relies on portfolio maturities and sales to help fund operations.
• Quarterly losses have been persistent: Net losses have consistently remained in the tens of millions per quarter for years.
• R&D spending surged: Research and development expense jumped to $177.3 million in Q1 2026 from $23.2 million in Q4 2025.
• Operating cash burn continues: The company posted negative operating cash flow of $27.3 million in Q1 2026.
• Acquisition spending was large: The $150 million acquisition outflow materially increased investing cash usage in the quarter.

Longer term, the trend is clear: Erasca has not yet shown commercial revenue, and its quarterly operating losses have been persistent since at least 2022. However, unlike many early-stage biotech names, the company still has a sizable cash and investment base, which reduces near-term financing pressure. Investors will likely focus on whether the recent acquisition and higher R&D spending can accelerate clinical progress enough to justify the cash burn.

Bottom line: Erasca’s financial position is still stable from a liquidity standpoint, but the business remains highly speculative. The company has enough cash to keep advancing its pipeline for now, yet it must eventually translate that spending into clinical wins or it will remain a dilution-dependent biotech story.